Loading…
REGENXBIO Inc. is projected to rise to $16.81 by 2027, a +73% move from its current price of $9.69. RGNX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $9.26 | $9.71 | $10.19 | +0.25% |
| Aug 3 | $9.10 | $9.74 | $10.42 | +0.49% |
| Aug 4 | $8.99 | $9.76 | $10.60 | +0.74% |
| Aug 5 | $8.89 | $9.79 | $10.77 | +0.99% |
| Aug 6 | $8.81 | $9.81 | $10.92 | +1.24% |
| Aug 7 | $8.75 | $9.83 | $11.06 | +1.49% |
| Aug 8 | $8.69 | $9.86 | $11.19 | +1.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.69 | $9.86 | $11.19 | +1.74% |
| Week 2 | $8.39 | $10.03 | $11.99 | +3.50% |
| Week 3 | $8.20 | $10.20 | $12.70 | +5.30% |
| Week 4 | $8.06 | $10.38 | $13.37 | +7.12% |
| Week 5 | $7.96 | $10.56 | $14.01 | +8.98% |
| Week 6 | $7.88 | $10.74 | $14.65 | +10.87% |
| Week 7 | $7.82 | $10.93 | $15.28 | +12.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
REGENXBIO Inc. is a clinical-stage biotechnology company that provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
The company's pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II, and RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. It has collaboration and license agreements with AbbVie Global Enterprises Ltd.
to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
REGENXBIO Inc. (RGNX) is currently priced at $9.89 with a market capitalization of $534.22M and ranks 2882 by market cap. The price outlook shown in the forecast highlights upside potential across multiple years, with the average price rising from $9.89 in 2026 to higher levels in subsequent years (e.g., $17.18 in 2027, $20.77 in 2028, $23.34 in 2029, $22.51 in 2030, $78.11 in 2040, and $148.95 in 2050), and a 2050 max of $342.59.
This suggests meaningful longer-term upside despite a flat 2026 starting point on average.
A major floor 67.0% below — a decisive break under it would weaken the trend.
The nearest floor, 19.5% below — buyers have tended to step in here.
The nearest ceiling, 61.5% above — a clean break opens room to run.
A major ceiling 95.0% above — clearing it would confirm fresh momentum.
Key RGNX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RGNX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.75 | Sell | $9.84 | Sell |
| MA 10 | $9.96 | Sell | $10.17 | Sell |
| MA 20 | $11.63 | Sell | $10.55 | Sell |
| MA 50 | $9.46 | Buy | $10.11 | Sell |
| MA 100 | $9.09 | Buy | $9.81 | Sell |
| MA 200 | $10.57 | Sell | $9.89 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.77 | Neutral |
| Stoch RSI (14) | 11.10 | Buy |
| CCI (20) | -68.44 | Neutral |
| Williams %R (14) | -96.65 | Info |
| MACD (12,26,9) | -0.34 | Sell |
| ROC (12) | -21.03 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 3.35 | Buy |
| TRIX (15) | 0.27 | Buy |
| Awesome (5,34) | -1.10 | Sell |
| Ultimate (7,14,28) | 32.90 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 9.71 | Sell |
| ADX (14) | 23.46 | Sell |
| ATR (14) | 0.44 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 40, indicating a neutral momentum stance. The 50-day simple moving average sits at $9.17 and the 200-day simple moving average at $10.61. Near-term support is shown at $6.08 and resistance at $15.65, with a 30-day price range from $6.64 to $14.74.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.65 | $9.69 | $17.28 | 0% | Neutral | |
| $12.49 | $16.81 | $24.38 | +73% | Bullish | |
| $14.24 | $20.22 | $31.12 | +109% | Bullish | |
| $15.33 | $22.79 | $36.70 | +135% | Bullish | |
| $16.02 | $24.81 | $41.49 | +156% | Bullish | |
| $16.24 | $26.12 | $45.12 | +170% | Bullish | |
| $18.47 | $30.79 | $54.74 | +218% | Bullish | |
| $27.30 | $47.10 | $85.91 | +386% | Bullish | |
| $30.04 | $53.58 | $100.04 | +453% | Bullish | |
| $28.89 | $53.23 | $101.56 | +449% | Bullish | |
| $43.86 | $94.30 | $196.66 | +873% | Bullish | |
| $85.67 | $190.38 | $437.87 | +18.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.65 | $9.69 | $12.69 | +0.00% |
| September 2026 | $9.57 | $11.57 | $14.58 | +19.45% |
| October 2026 | $9.90 | $12.12 | $15.55 | +4.75% |
| November 2026 | $9.90 | $12.24 | $15.92 | +0.95% |
| December 2026 | $10.50 | $13.11 | $17.28 | +7.13% |
Click any year to see its month-by-month RGNX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RGNX is projected to trade between $5.65 and $17.28, averaging $9.69 — a potential gain of 0% from today's $9.69. Price action looks broadly range-bound.
REGENXBIO Inc.'s 2027 outlook centres on $16.81, within a $12.49 to $24.38 range. That is up +73% on the projected 2026 average. That marks a +73% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, RGNX could reach as high as $31.12, with a base case around $20.22 and support toward $14.24 — roughly +109% from $9.69. Momentum favours further upside here.
Expect RGNX to range from $15.33 to $36.70 through 2029. The $22.79 average target implies a +135% move from current prices. That is up +13% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The RGNX price prediction for 2030 points to an average of $24.81 (low $16.02, high $41.49) — a potential gain of +156% on today's $9.69. Momentum favours further upside here.
In 2031, RGNX is projected to trade between $16.24 and $45.12, averaging $26.12 — a potential gain of +170% from today's $9.69. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
REGENXBIO Inc.'s 2032 outlook centres on $30.79, within a $18.47 to $54.74 range. That is up +18% on the projected 2031 average. That marks a +218% change versus current levels. Momentum favours further upside here.
By 2033, RGNX could reach as high as $85.91, with a base case around $47.10 and support toward $27.30 — roughly +386% from $9.69. Buyers look set to stay in control over this stretch.
Expect RGNX to range from $30.04 to $100.04 through 2034. The $53.58 average target implies a +453% move from current prices. That is up +14% on the projected 2033 average. Momentum favours further upside here.
The RGNX price prediction for 2035 points to an average of $53.23 (low $28.89, high $101.56) — a potential gain of +449% on today's $9.69. Buyers look set to stay in control over this stretch.
In 2040, RGNX is projected to trade between $43.86 and $196.66, averaging $94.30 — a potential gain of +873% from today's $9.69. That is up +77% on the projected 2035 average. Momentum favours further upside here.
REGENXBIO Inc.'s 2050 outlook centres on $190.38, within a $85.67 to $437.87 range. That is up +102% on the projected 2040 average. That marks a +18.6x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in RGNX today (≈ 103.199174 RGNX) could be worth
$19,647.05
+$18,647.05 (+1865%) by 2050 · US Dollar
Based on the average projected RGNX price of $190.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RGNXwould be worth at today's price.
$1,000 invested in RGNX on Jul 31, 2025 (≈ 117.50881 RGNX) would be worth
$1,138.66
+$138.66 (+13.9%) today · 1.14× · US Dollar
Based on a RGNX entry price of $8.51 vs. today's $9.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.73 | $995.89 | -0.4% |
| 1 month ago | $13.09 | $740.26 | -26.0% |
| 3 months ago | $9.12 | $1,062.5 | +6.3% |
| 6 months ago | $10.78 | $898.89 | -10.1% |
| 1 year ago | $8.51 | $1,138.66 | +13.9% |
| All time (5.0y) ago | $31.96 | $303.19 | -69.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RGNX forecast.
Our base-case forecast reaches $19.00 around 2028.
Implied market cap at $19.00: $1.22B
The multi-year forecast portrays a bullish trajectory, with notable milestones in the 2030, 2040 and 2050 horizons. The 2030 forecast lists an average price of $22.51 with a min of $13.93 and a max of $39.05, yielding a 127.6% ROI and a bullish sentiment. By 2040, the average is projected at $78.11 with a min of $35.15 and a max of $171.43, delivering a 689.8% ROI in a bullish stance.
In 2050, the average is $148.95 with a min of $67.03 and a max of $342.59, for a 1406.1% ROI and continued bullish outlook. These figures are estimates and not guarantees, but they illustrate substantial upside potential over the long term while acknowledging inherent uncertainty and market volatility.
Tap a question to reveal the answer.
Avg $22.51, min $13.93, max $39.05, ROI 127.6, sentiment BULLISH.
Forecasts show BULLISH sentiment with rising avg prices across years, including 2027 avg $17.18, 2028 avg $20.77, 2030 avg $22.51, 2040 avg $78.11, and 2050 avg $148.95; max in 2050 $342.59. These are estimates and not guarantees.
Yes, the max forecast for 2050 is $342.59.
Current price $9.89; market cap $534.22M.
Sentiment NEUTRAL; RSI 14 is 40; SMA50 is $9.17; SMA200 is $10.61; 30-day range is $6.64 to $14.74; support $6.08; resistance $15.65.
REGENXBIO Inc. Community Discussion
0Share your REGENXBIO Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.